| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4163937
Max Phase: Preclinical
Molecular Formula: C26H26N2O6
Molecular Weight: 462.50
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC1=C(C(=O)OCc2ccccc2)C(c2cc([N+](=O)[O-])ccc2O)C2=C(CCC(C)(C)C2=O)N1
Standard InChI: InChI=1S/C26H26N2O6/c1-15-21(25(31)34-14-16-7-5-4-6-8-16)22(18-13-17(28(32)33)9-10-20(18)29)23-19(27-15)11-12-26(2,3)24(23)30/h4-10,13,22,27,29H,11-12,14H2,1-3H3
Standard InChI Key: URHYRIOLINAHDV-UHFFFAOYSA-N
Associated Targets(non-human)
Voltage-gated L-type calcium channel alpha-1C subunit 1321 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 462.50 | Molecular Weight (Monoisotopic): 462.1791 | AlogP: 4.65 | #Rotatable Bonds: 5 |
| Polar Surface Area: 118.77 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 6.80 | CX Basic pKa: | CX LogP: 4.60 | CX LogD: 3.92 |
| Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.38 | Np Likeness Score: -0.40 |
References
| 1. Schaller D, Gündüz MG, Zhang FX, Zamponi GW, Wolber G.. (2018) Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity., 155 [PMID:29843108] [10.1016/j.ejmech.2018.05.032] |
Source
Source(1):